Morepen Laboratories Ltd.

BSE: MOREPENLAB500288ISIN INE083A01026

Healthcare
Pharmaceuticals
BSE 1000

Share price

₹100.25-2.40 (-2.34%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹150.80
52W low: ₹33.44
Off 52W high: -33.52%
1M return: -25.91%
3M return: +30.25%
6M return: +130.14%
1Y return: +107.94%
20D avg volume: 5,59,707
50 DMA: ₹118.32
200 DMA: ₹65.80

Key ratios Consolidated

Market cap: ₹5,493 Cr
Current price: ₹100.25
52W high / low: ₹150.80 / ₹33.44
Face value: ₹2.00
P/E: 29.13
P/B: 3.98
EPS (TTM): ₹3.44
Book value / share: ₹25.21
ROE: —
ROCE: 9.40%
Operating margin: —
Net margin: —
Debt / equity: 0.16
Net debt: ₹163.50 Cr
Interest cover: 8.31
Dividend yield: 0.20%
Dividend / share (TTM): ₹0.20
Payout: 5.81%
Cash conversion cycle: 58.1 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	746.50	570.13	484.72	484.16	411.58	425.24	465.85	452.78	437.73	455.22	423.07	444.55
	8.69	5.18	8.46	3.81	4.64	4.41	4.61	5.34	4.99	3.43	4.24	4.07
	755.19	575.31	493.18	487.97	416.21	429.65	470.46	458.12	442.71	458.64	427.32	448.62
	638.65	500.78	469.89	452.55	396.34	414.13	444.75	422.91	396.69	410.48	385.12	404.61
	411.91	328.38	290.58	294.19	220.63	237.71	268.43	239.52	256.22	235.01	220.26	235.60
	6.95	9.64	17.67	15.77	31.98	17.04	71.31	40.67	39.29	55.97	30.09	45.60
	79.69	62.44	58.76	62.09	56.65	55.24	57.01	54.28	49.67	47.95	47.94	46.80
	5.19	4.84	3.88	4.32	4.18	4.04	4.67	1.34	1.18	1.15	0.80	2.17
	10.07	8.35	5.75	10.38	11.28	9.03	16.47	4.93	1.86	5.73	9.62	8.45
	154.85	106.45	101.99	78.42	60.04	83.47	50.85	37.08	31.50	28.54	34.87	29.24
	116.54	74.53	23.29	35.42	19.87	15.52	25.71	35.21	46.02	48.17	42.20	44.02
	0.00	0.00	0.00	0.00	25.83	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	116.54	74.53	23.29	35.42	45.70	15.52	25.71	35.21	46.02	48.17	42.20	44.02
	27.65	18.18	7.59	7.93	4.65	4.11	5.40	8.52	11.17	12.00	13.46	12.03
	88.89	56.40	15.74	27.51	40.88	10.75	20.32	26.69	34.85	36.17	28.28	31.99
	1.62	1.03	0.28	0.50	0.75	0.20	0.35	0.49	0.65	0.71	0.54	0.63
Key metrics
	131.80	87.72	32.92	50.12	61.16	28.59	46.85	41.48	49.06	55.05	52.62	54.64
	17.70%	15.40%	6.80%	10.40%	14.90%	6.70%	10.10%	9.20%	11.20%	12.10%	12.40%	12.30%
	11.90%	9.90%	3.20%	5.70%	9.90%	2.50%	4.40%	5.90%	8.00%	7.90%	6.70%	7.20%
	7.70%	—	1.90%	—	3.90%	—	2.40%	—	—	—	—	—
	81.40%	34.10%	4.10%	6.90%	-6.00%	-6.60%	10.10%	1.90%	—	—	—	—
	117.40%	424.70%	-22.50%	3.10%	17.30%	-70.30%	-28.10%	-16.60%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	2,286	1,806	1,812	1,690	1,418	1,547
	26.14	21.31	18.36	13.97	6.13	10.31
	2,312	1,827	1,830	1,704	1,424	1,557
	2,062	1,733	1,675	1,569	1,368	1,430
	1,325	1,043	999.18	883.31	781.41	797.13
	50.03	82.46	207.25	177.00	157.85	262.23
	262.98	232.74	208.91	181.47	154.68	164.25
	18.23	16.41	8.34	3.71	1.98	7.37
	34.55	36.44	28.98	33.47	27.93	27.64
	441.71	323.91	269.28	121.99	93.95	78.45
	249.78	94.09	155.11	135.42	55.76	126.70
	0.00	25.83	0.00	0.00	0.00	0.00
	249.78	119.92	155.11	135.42	55.76	126.70
	61.35	24.27	37.09	38.80	17.08	25.02
	188.54	94.88	118.02	96.16	38.67	101.68
	3.43	1.73	2.20	1.88	0.77	2.26
Key metrics
	302.56	172.77	192.43	172.60	85.67	161.71
	13.24%	9.60%	10.60%	10.20%	6.00%	10.50%
	8.25%	5.30%	6.50%	5.70%	2.70%	6.60%
	—	9.40%	12.80%	—	—	—
	30.20%	-0.30%	7.20%	19.30%	-8.40%	—
	91.14%	-19.60%	22.70%	148.70%	-62.00%	—
	—	-52.88	-91.97	—	—	—
	—	0.34	0.27	—	—	—
	—	0.16	0.07	—	—	—
	—	163.50	52.01	—	—	—
	—	58.1	52.6	—	—	—
Balance sheet
	—	1,936	1,778	—	—	—
	—	1,164	1,159	—	—	—
	—	31.19	27.38	—	—	—
	—	333.14	324.76	—	—	—
	—	271.83	299.96	—	—	—
	—	450.52	395.74	—	—	—
	—	381.16	316.51	—	—	—
	—	317.24	363.30	—	—	—
	—	490.30	500.65	—	—	—
	—	194.69	79.39	—	—	—
	—	61.09	53.63	—	—	—
	—	133.60	25.76	—	—	—
	—	1,247	1,187	—	—	—
Cash flow
	—	32.64	32.06	—	—	—
	—	-123.42	-321.51	—	—	—
	—	97.40	299.89	—	—	—
	—	85.52	124.03	—	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	678.00	541.04	462.81	457.57	369.53	391.28	381.94	403.25	383.70	385.64	392.60	394.63
	8.43	5.31	8.82	3.93	4.65	4.09	3.14	4.87	4.63	3.07	3.99	3.66
	686.43	546.35	471.63	461.50	374.18	395.38	385.08	408.13	388.33	388.71	396.59	398.29
	582.78	474.20	444.00	430.08	356.41	384.02	367.78	377.75	345.48	341.67	343.88	351.07
	411.91	328.38	290.58	294.19	220.63	237.71	268.43	239.52	256.22	235.01	220.26	235.60
	1.09	4.35	5.00	1.62	7.09	1.31	5.77	5.77	3.47	5.81	2.33	9.00
	71.76	55.78	54.37	55.61	49.61	46.69	48.15	46.30	42.84	39.94	40.17	40.32
	5.10	4.78	3.87	4.31	4.11	3.81	3.74	1.27	1.05	1.04	0.73	2.04
	9.70	7.98	0.63	10.09	10.70	7.88	12.25	4.81	3.79	3.59	6.69	5.51
	113.53	93.24	95.07	75.07	54.54	76.80	50.90	35.69	29.63	26.36	32.29	27.02
	103.65	72.15	27.63	31.42	17.77	11.35	17.30	30.38	42.86	47.05	52.71	47.22
	0.00	0.00	0.00	0.00	1.10	0.00	0.00	—	—	—	—	—
	103.65	72.15	27.63	31.42	18.86	11.35	17.30	30.38	42.86	47.05	52.71	47.22
	25.78	18.15	7.50	7.93	4.49	3.29	5.39	7.69	10.93	12.00	12.75	12.02
	77.87	54.00	20.12	23.50	14.38	8.06	11.91	22.69	31.93	35.05	39.96	35.20
	1.42	0.99	0.37	0.43	0.26	0.15	0.20	0.41	0.60	0.69	0.78	0.69
Key metrics
	118.45	84.91	32.13	45.82	33.67	23.04	33.29	36.46	47.70	51.68	60.13	54.77
	17.50%	15.70%	6.90%	10.00%	9.10%	5.90%	8.70%	9.00%	12.40%	13.40%	15.30%	13.90%
	11.50%	10.00%	4.30%	5.10%	3.90%	2.10%	3.10%	5.60%	8.30%	9.10%	10.20%	8.90%
	6.50%	—	2.00%	—	1.80%	—	1.70%	—	—	—	—	—
	83.50%	38.30%	21.20%	13.50%	-3.70%	1.50%	-2.70%	2.20%	—	—	—	—
	441.50%	570.00%	68.90%	3.60%	-55.00%	-77.00%	-70.20%	-35.50%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	2,139	1,681	1,555	1,538	1,339	1,449
	26.49	21.50	15.72	12.57	5.76	10.23
	2,166	1,703	1,570	1,550	1,345	1,460
	1,931	1,615	1,433	1,401	1,282	1,334
	1,325	1,043	999.18	883.31	781.41	797.13
	12.06	15.02	20.81	61.84	105.07	191.68
	237.52	206.28	177.22	160.28	146.19	150.00
	18.06	16.10	7.10	3.51	1.98	7.37
	28.40	29.31	24.44	21.90	18.01	21.19
	376.91	301.48	248.27	115.17	89.42	72.98
	234.85	88.17	137.59	148.98	63.04	125.54
	0.00	1.10	0.00	—	—	—
	234.85	89.26	137.59	148.98	63.04	125.54
	59.36	23.21	36.01	38.04	16.80	24.48
	175.49	66.06	101.58	110.94	46.24	101.06
	3.21	1.21	1.90	2.17	0.92	2.25
Key metrics
	281.31	134.67	169.13	174.39	83.03	154.10
	13.15%	8.00%	10.90%	11.30%	6.20%	10.60%
	8.20%	3.90%	6.50%	7.20%	3.50%	7.00%
	—	6.70%	11.50%	—	—	—
	38.38%	8.10%	1.10%	14.80%	-7.60%	—
	207.66%	-35.00%	-8.40%	139.90%	-54.20%	—
	—	-63.29	-94.87	—	—	—
	—	0.31	0.29	—	—	—
	—	0.16	0.07	—	—	—
	—	183.02	54.53	—	—	—
	—	54.4	56.7	—	—	—
Balance sheet
	—	1,908	1,721	—	—	—
	—	1,238	1,107	—	—	—
	—	10.57	24.43	—	—	—
	—	333.19	293.75	—	—	—
	—	154.26	286.39	—	—	—
	—	682.00	390.91	—	—	—
	—	307.52	315.89	—	—	—
	—	236.84	338.41	—	—	—
	—	346.29	461.56	—	—	—
	—	193.59	78.96	—	—	—
	—	60.73	53.20	—	—	—
	—	132.86	25.76	—	—	—
	—	1,243	1,182	—	—	—
Cash flow
	—	20.47	29.08	—	—	—
	—	-119.02	-280.42	—	—	—
	—	97.12	260.47	—	—	—
	—	83.76	123.95	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +7.88%
Sales CAGR 5Y: —
Profit CAGR 3Y: +12.63%
Profit CAGR 5Y: —
Sales YoY (TTM): +38.38%
Profit YoY (TTM): +207.66%

Consolidated

Sales CAGR 3Y: +8.40%
Sales CAGR 5Y: —
Profit CAGR 3Y: +34.88%
Profit CAGR 5Y: —
Sales YoY (TTM): +30.20%
Profit YoY (TTM): +91.14%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 35.64%

Quarter	September 2026	June 2026
Promoter %	35.64%	35.64%

Holder	Type	Holding	Previous	Change
PINFOLD OVERSEAS LIMITED	Public	6.39%	7.03%	-0.64%
SCOPE CREDITS AND FINANCIAL SERVICES PVT. LTD.	Promoter Group	2.84%	2.84%	0.00%
CONCEPT CREDITS AND CONSULTANTS PVT. LTD.	Promoter Group	2.80%	2.80%	0.00%
BROOK INVESTMENTS AND FINANCIAL SERVICES PVT. LTD	Promoter Group	2.77%	2.77%	0.00%
SOLITARY INVESTMENTS AND FINANCIAL SERVICES PVT. LTD.	Promoter Group	2.76%	2.76%	0.00%
SOLACE INVESTMENTS AND FINANCIAL SERVICES PVT. LTD.	Promoter Group	2.75%	2.75%	0.00%
MID MED FINANCIAL SERVICES AND INVESTMENTS PVT. LTD.	Promoter Group	2.73%	2.73%	0.00%
REACT INVESTMENTS AND FINANCIAL SERVICES PVT. LTD.	Promoter Group	2.73%	2.73%	0.00%
EPITOME HOLDINGS PVT.LTD.	Promoter Group	2.65%	2.65%	0.00%
SEED SECURITIES AND SERVICES PVT. LTD.	Promoter Group	2.61%	2.61%	0.00%
SQUARE INVESTMENTS AND FINANCIAL SERVICES PVT. LTD.	Promoter Group	2.57%	2.57%	0.00%
MOREPEN LABORATORIES LIMITED	Public	1.02%	1.02%	0.00%
SUSHIL SURI	Promoter	1.00%	1.00%	0.00%
ANJU SURI	Promoter Group	0.95%	0.95%	0.00%
LIQUID HOLDINGS PVT. LTD.	Promoter Group	0.91%	0.91%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Morepen Laboratories Ltd.	5,493	100.25	29.13	9.40%	+30.20% TTM	+91.14% TTM	+107.94%

Filings & corporate actions

Recent announcements

Change in Senior Management Personnel on account of resignation31 Oct 2026 · Company Update / Change in Management
Newspaper Publication financial results for the quarter and half year ended 30 September 2026 and special window for transfer and dematerialization of physical shares28 Oct 2026 · Company Update / Newspaper Publication
Change in Designation of Senior Management Personnel of the Company27 Oct 2026 · Company Update / Change in Management
Please find attached the monitoring agency report for the quarter ended September 30, 202627 Oct 2026 · Company Update / Monitoring Agency Report
Please find attached the Investor Presentation for Q2 & H1 FY 27 Financial Results27 Oct 2026 · Company Update / Investor Presentation
Please find attached the press release27 Oct 2026 · Company Update / Press Release / Media Release
Please find attached the Q2 & H1 FY 27 Financial Results27 Oct 2026 · Result / Financial Results
Please find attached the Q2 & H1 FY27 Financial Results along with Limited Review Report27 Oct 2026 · Board Meeting / Outcome of Board Meeting
Morepen Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve financial results for ....22 Oct 2026 · Board Meeting / Board Meeting
Please find attached the disclosure14 Oct 2026 · Company Update / General
Closure of Trading Window for the quarter ended 30 September 202628 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Please find attached the press release28 Sep 2026 · Company Update / Press Release / Media Release (Revised)
Please find attached the Voting Results and the Scrutinizer Report of 41st Annual General Meeting26 Sep 2026 · AGM/EGM / AGM
Proceedings of 41st Annual General meeting of the Company26 Sep 2026 · AGM/EGM / AGM
Please find attached the file22 Sep 2026 · Company Update / General
Business Update-First Phase of Manufacturing Capacity Expansion Completed Ahead of Schedule7 Sep 2026 · Company Update / General
Newspaper publication for completion of dispatch of the notice of 41st AGM and Annual report for the FY 2025-263 Sep 2026 · Company Update / Newspaper Publication
Please find attached the specimen letter2 Sep 2026 · Company Update / General
Please find attached the BRSR for the financial year ended March 31, 20262 Sep 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Please find enclosed notice of 41st AGM scheduled to be held on Saturday 26th September 2026 at 1:00 p.m. through VC/OAVM.2 Sep 2026 · AGM/EGM / AGM
Please find attached the Annual Report for the financial year 2025-26 along with notice of 41st AGM2 Sep 2026 · Others / Reg. 34 (1) Annual Report
Newspaper publication-information relating to 41st Annual General Meeting, Dividend and record date26 Aug 2026 · Company Update / Newspaper Publication
Allotment of equity shares by Morepen RX Limited, wholly owned subsidiary of the company6 Aug 2026 · Company Update / Acquisition
Newspaper Publication Financial Results for the quarter ended June 30, 20265 Aug 2026 · Company Update / Newspaper Publication
Please find attached the monitoring agency report for the quarter ended June 30, 20264 Aug 2026 · Company Update / Monitoring Agency Report
41st Annual General Meeting scheduled to be held on September 26, 20264 Aug 2026 · Company Update / General
Re-appointment of Mr. Sushil Suri as Chairman & Managing Director w.e.f. October 20, 20264 Aug 2026 · Company Update / Change in Management
Please find attached the file4 Aug 2026 · Corp. Action / Record Date
Please find attached the Press Release4 Aug 2026 · Company Update / Press Release / Media Release
Please find attached the Q1 FY 27 Investor Presentation4 Aug 2026 · Company Update / Investor Presentation
Please find attached the Q1 FY 27 Financial Results4 Aug 2026 · Board Meeting / Outcome of Board Meeting
Please find attached the Q1 FY 27 Financial Results4 Aug 2026 · Result / Financial Results
Morepen Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2026 ,inter alia, to consider and approve financial results for ....28 Jul 2026 · Board Meeting / Board Meeting
The name of wholly owned subsidiary company has been changed from Morepen Labs - FZCO to Morepen Labs FZE23 Jul 2026 · Company Update / General
Change in Senior Management Personnel on account of Resignation6 Jul 2026 · Company Update / Change in Management
Please find enclosed the Press Release1 Jul 2026 · Company Update / Press Release / Media Release
Elevation and change in designation of Mr. Sanjay Suri30 Jun 2026 · Company Update / Change in Management
closure of trading window for DP and their immediate relatives for the quarter ended 30 June 202626 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Please find enclosed the reply10 Jun 2026 · Company Update / General
The Exchange has sought clarification from Morepen Laboratories Ltd on June 10, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited.10 Jun 2026 · Company Update / Clarification

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 0.2000	18 Sep 2026	19 Sep 2026	—
Final Dividend - Rs. - 0.2000	29 Aug 2025	30 Aug 2025	—

Board meetings

27 Oct 2026 Board Meeting - Financial Results
4 Aug 2026 Board Meeting - Financial Results